Related Experiment Video
Updated: Apr 28, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Therapeutic efficacy of intravenously administered transferrin-conjugated dendriplexes on prostate carcinomas
Aim:
Improved treatments for prostate cancer are critically needed in order to overcome metastasis and lethal recurrence. Intravenously administered gene therapy would be an attractive anticancer treatment strategy; however, the lack of suitable carrier systems able to selectively deliver therapeutic genes to tumors has so far limited this investigation. Given that transferrin receptors are overexpressed on prostate cancer cells, the purpose of this study is to determine whether transferrin-conjugated dendriplexes encoding TNF-α, TNF-related apoptosis-inducing ligand and IL-12 would suppress the growth of prostate cancer cell lines in vitro and in vivo.
Materials & Methods:
Transferrin-conjugated dendriplexes encoding TNF-α, TNF-related apoptosis-inducing ligand and IL-12 were intravenously administered to mice bearing subcutaneous PC-3 and DU145 tumors.
Results:
The administration of the transferrin-conjugated generation 3 diaminobutyric polypropylenimine dendriplex encoding TNF-a resulted in tumor suppression for 60% of PC-3 and 50% of DU145 prostate tumors.
Conclusion:
These dendriplexes hold great potential as a novel approach for prostate cancer therapy.
Insights
Transferrin-conjugated dendriplexes effectively suppressed prostate cancer growth in mice. This novel gene therapy approach shows promise for treating advanced prostate cancer by targeting tumor cells.
Area of Science:
- Oncology
- Gene Therapy
- Nanotechnology
Background:
- Prostate cancer metastasis and recurrence necessitate improved treatment strategies.
- Intravenous gene therapy is a promising strategy, but requires effective tumor-targeting carriers.
- Transferrin receptors are overexpressed on prostate cancer cells, offering a potential targeting mechanism.
Purpose of the Study:
- To evaluate transferrin-conjugated dendriplexes carrying therapeutic genes (TNF-α, TNF-related apoptosis-inducing ligand, IL-12) for prostate cancer treatment.
- To determine the efficacy of these dendriplexes in suppressing prostate cancer cell growth in vitro and in vivo.
Main Methods:
- Development of transferrin-conjugated dendriplexes encoding TNF-α, TNF-related apoptosis-inducing ligand, and IL-12.
- Intravenous administration of these dendriplexes to mice with subcutaneous PC-3 and DU145 prostate tumors.
Main Results:
- Administration of transferrin-conjugated generation 3 diaminobutyric polypropylenimine dendriplexes encoding TNF-α resulted in significant tumor suppression.
- Tumor suppression was observed in 60% of PC-3 and 50% of DU145 prostate tumors.
Conclusions:
- Transferrin-conjugated dendriplexes demonstrate potential as a novel therapeutic strategy for prostate cancer.
- This approach offers a promising avenue for targeted gene delivery and cancer treatment.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
08:55Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
Published on: April 15, 2016